Drug-drug interactions of drugs for treatment of overactive bladder
Abstract
Spoteby lk uvanch pro lbu hyperaktivnho moovho mche (OAB) v R za poslednch 10 let vrazn stouply a nepochybn stoup i poet potencilnch lkovch interakc tchto lk. Tento pehledov lnek shrnuje souasn poznatky o zmnn problematice tak, aby oetujcm lkam poskytl informace potebn pro optimln farmakoterapii OAB, ke kter pat i individuln vbr lk s ohledem na stav pacienta i na lky, kter souasn pacient uv na jin onemocnn.
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.